Morgan is currently group president of Icon early phase and laboratory services, and prior to that was chief operating officer of the Icon clinical research division, having joined Icon in 2006.

Icon has also appointed Linda Meyerson chief operating officer (COO), who is expected to report directly to Morgan and brings over 30 years of pharmaceutical industry experience and drug development knowledge to the organisation.

Icon also announced that John Hubbard, the former group president, clinical research services, is leaving the organisation to take up a senior role in a global biopharmaceutical company.

Icon CEO Peter Gray said that Alan has been an outstanding member of their management team, and his deep knowledge of their clinical organisation and broad industry experience will be invaluable as they continue to develop the business.